Literature DB >> 7686316

Monoclonal antibody neutralization of BPV-1.

N D Christensen1, J W Kreider.   

Abstract

Mouse monoclonal antibodies were generated against intact infectious BPV-1 virions by methods previously described (Christensen et al., 1990). ELISA was used to screen for reactivities to intact and/or disrupted BPV-1, CRPV and HPV-11 virions. Several hybridomas were initially selected that showed antibody reactivity by ELISA to both intact and disrupted BPV-1, to disrupted BPV-1 only, or to intact BPV-1 virions. One monoclonal antibody, designated B1.A1, which reacted only to intact BPV-1 was selected for virus neutralization analyses. ELISA demonstrated that this monoclonal antibody bound to intact BPV-1 virions, but not to intact CRPV, HPV-11 or to disrupted papillomavirus (PV) antigens. Strong neutralization of BPV-1-induced focus formation of mouse C127 cells by monoclonal B1.A1 was observed. The neutralization titer was equivalent to the neutralization titer obtained with a polyclonal rabbit anti-BPV-1 virion antisera, and directly correlated with antibody concentration as determined by ELISA. These results extend our previous analyses on the epitopes of infectious papillomaviruses as defined by monoclonal antibodies that identify neutralizing epitopes. The nature of these epitopes is such that maintenance of the quaternary structure of the infectious virions is necessary for preservation of the antigenicity of the neutralizing epitope.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686316     DOI: 10.1016/0168-1702(93)90136-b

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus.

Authors:  Brian S Bowser; Horng-Shen Chen; Michael J Conway; Neil D Christensen; Craig Meyers
Journal:  Virus Res       Date:  2011-07-06       Impact factor: 3.303

3.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Interaction of papillomaviruses with the cell surface.

Authors:  R B Roden; R Kirnbauer; A B Jenson; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.

Authors:  Saeed Shafti-Keramat; Christina Schellenbacher; Alessandra Handisurya; Neil Christensen; Bärbel Reininger; Sabine Brandt; Reinhard Kirnbauer
Journal:  Virology       Date:  2009-09-03       Impact factor: 3.616

6.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Authors:  Alessandra Handisurya; Sabine Gilch; Dorian Winter; Saeed Shafti-Keramat; Dieter Maurer; Hermann M Schätzl; Reinhard Kirnbauer
Journal:  FEBS J       Date:  2007-02-20       Impact factor: 5.542

8.  Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice.

Authors:  Eduardo Zamora; Alessandra Handisurya; Saeed Shafti-Keramat; David Borchelt; Gay Rudow; Katherine Conant; Christopher Cox; Juan C Troncoso; Reinhard Kirnbauer
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.